XML 80 R57.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Non-Controlling Interests - Spero Cantab - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 22 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2017 USD ($) | Jul. 31, 2017 USD ($) | Jun. 30, 2016 USD ($) Option shares | Mar. 31, 2018 USD ($) Option | Mar. 31, 2017 USD ($) | Dec. 31, 2017 USD ($) Option | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Mar. 31, 2018 USD ($) Option
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | $ 8,925,000 | $ 5,999,000 | $ 32,869,000 | $ 26,333,000 | $ 11,125,000 |
Non-controlling interest | $ 355,000 |  |  | 355,000 |  | 355,000 | $ (3,808,000) |  | $ 355,000
Spero Cantab [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  | 12.50% |  |
Non-controlling interest | 0 |  |  | $ 0 |  | 0 | $ 1,303,000 |  | $ 0
Spero Cantab [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Common stock shares issued | shares |  |  | 125 |  |  |  |  |  |
Ownership percentage |  |  | 12.50% |  |  |  |  |  |
Common stock issued, aggregate fair value |  |  | $ 1,600,000 |  |  |  |  |  |
Upfront consideration |  |  | 300,000 |  |  |  |  |  |
Non-controlling interest |  |  | 1,600,000 |  |  |  |  |  |
Cash payment for repurchase of shares |  | $ 200,000 |  |  |  |  |  |  |
Spero Cantab [Member] | Cantab Agreements [Member] | Contingent Milestone Payments [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Cash payment for repurchase of shares |  | $ 100,000 |  |  |  |  |  |  |
Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Research and development expense |  |  | $ 300,000 |  |  |  |  |  |
Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] | Niaid [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Number of option period for funding from government contract | Option |  |  | 3 |  |  |  |  |  |
Maximum received fund | 1,300,000 |  |  |  |  | $ 1,300,000 |  |  |
Maximum potential funding from government contract |  |  | $ 6,000,000 |  |  |  |  |  |
Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] | Niaid [Member] | First Option [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Number of option period for funding from government contract committed to date | Option |  |  |  | 2 |  | 2 |  |  | 2
Committed amount from government contract to date |  |  |  | $ 5,400,000 |  | $ 5,100,000 |  |  | $ 5,400,000
Spero Cantab [Member] | New Pharma License Holding Limited [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Research and development expense |  |  | 1,600,000 |  |  |  |  |  |
Spero Cantab [Member] | Pro Bono Bio PLC [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Maximum amounts of investments for anti-dilution protection |  |  | $ 8,000,000 |  |  |  |  |  |
Spero Cantab [Member] | Pro Bono Bio PLC [Member] | Cantab Agreements [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Ownership percentage |  |  | 5.00% |  |  |  |  |  |
Spero Cantab [Member] | Pro Bono Bio PLC [Member] | Cantab Agreements [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Ownership percentage |  |  | 12.50% |  |  |  |  |  |
Spero Gyrase, Inc. [Member] |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  | 20.00% |  |
Non-controlling interest | $ 355,000 |  |  | $ 400,000 |  | $ 355,000 | $ 380,000 |  | $ 400,000

X
- Definition Maximum amounts of investments by parent that would trigger the anti-dilution protection. + References No definition available. + Details
Name: | spro_MaximumInvestmentAmountTriggeringAdditionalShareIssuance
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum potential funding from government contract + References No definition available. + Details
Name: | spro_MaximumPotentialFundingFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum received fund amount. + References No definition available. + Details
Name: | spro_MaximumReceivedFundAmount
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of option period for funding from government contract. + References No definition available. + Details
Name: | spro_NumberOfOptionPeriodForFundingFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of option period for funding from government contract committed to date. + References No definition available. + Details
Name: | spro_NumberOfOptionPeriodForFundingFromGovernmentContractCommittedToDate
Namespace Prefix: | spro_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds from government contract + References No definition available. + Details
Name: | spro_ProceedsFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | spro_UpfrontPayments
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_MinorityInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_MinorityInterestLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow to reacquire common stock during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentsForRepurchaseOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=spro_SperoCantabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShareRepurchaseProgramAxis=spro_CantabAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=spro_CantabAntiInfectivesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spro_NiaidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OptionIndexedToIssuersEquityTypeAxis=spro_FirstOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=spro_NewPharmaLicenseHoldingLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=spro_ProBonoBioPLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=spro_SperoGyraseINCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |